Devimistat

Generic Name: Devimistat

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₈O_₂S_₂

CAS Number: 95809-78-2

Unique Ingredient Identifier: E76113IR49

Background: Devimistat (CPI-613) has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Advanced Cancer, and Pancreatic Cancer, among others.

Clinical Trials

Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients

Phase 2

Terminated

Conditions: Cancer

Interventions: Drug: CPI-613

First Posted Date: 2013-04-16

Last Posted Date: 2016-12-29

Lead Sponsor: Cornerstone Pharmaceuticals

Target Recruit Count: 7

Registration Number: NCT01832857

Locations: 🇺🇸
Eastchester Center for Cancer Care, Bronx, New York, United States

Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer

Phase 2

Withdrawn

Conditions: Metastatic Pancreatic Adenocarcinoma

Interventions: Drug: Any non-gemcitabine chemotherapies or best supportive care
Drug: CPI-613
Drug: Gemcitabine

First Posted Date: 2013-04-12

Last Posted Date: 2013-08-14

Lead Sponsor: Cornerstone Pharmaceuticals

Registration Number: NCT01830322

Locations: 🇺🇸
Temple Vasicek Cancer Treatment Center, Temple, Texas, United States
🇺🇸
Eastchester Center for Cancer Care, Bronx, New York, United States

CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Recurrent Adult Acute Myeloid Leukemia

Interventions: Drug: CPI-613
Drug: cytarabine
Drug: mitoxantrone hydrochloride
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2013-01-16

Last Posted Date: 2018-07-03

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 67

Registration Number: NCT01768897

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery

Phase 1

Completed

Conditions: Recurrent Adult Primary Liver Cancer
Recurrent Extrahepatic Bile Duct Cancer
Adult Primary Cholangiocellular Carcinoma
Advanced Adult Primary Liver Cancer
Cholangiocarcinoma of the Extrahepatic Bile Duct
Unresectable Extrahepatic Bile Duct Cancer
Cholangiocarcinoma of the Gallbladder
Localized Unresectable Adult Primary Liver Cancer
Metastatic Extrahepatic Bile Duct Cancer

Interventions: Drug: 6,8-bis(benzylthio)octanoic acid

First Posted Date: 2013-01-11

Last Posted Date: 2019-05-15

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 17

Registration Number: NCT01766219

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome

Phase 2

Withdrawn

Conditions: Acute Myeloid Leukemia (AML)
Myelodysplastic Syndrome (MDS)

Interventions: Drug: CPI-613

First Posted Date: 2012-01-30

Last Posted Date: 2016-12-29

Lead Sponsor: Cornerstone Pharmaceuticals

Registration Number: NCT01520805

Locations: 🇺🇸
Cornerstone Pharmaceuticals, Inc, Cranbury, New Jersey, United States

Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies

Phase 1

Completed

Conditions: Advanced Hematologic Malignancies

Interventions: Drug: CPI-613

First Posted Date: 2009-12-17

Last Posted Date: 2018-07-02

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 26

Registration Number: NCT01034475

Locations: 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients

Phase 1

Terminated

Conditions: Pancreatic Cancer
Cancer
Pancreatic Carcinoma

Interventions: Drug: CPI-613
Drug: Gemcitabine

First Posted Date: 2009-05-22

Last Posted Date: 2017-03-21

Lead Sponsor: Cornerstone Pharmaceuticals

Target Recruit Count: 6

Registration Number: NCT00907166

Locations: 🇺🇸
Eastchester Center for Cancer Care, Bronx, New York, United States
🇺🇸
Mary Crowley Cancer Research Centers, Dallas, Texas, United States

A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies

Phase 1

Completed

Conditions: Solid Tumors
Advanced Cancer
Advanced Malignancies
Lymphoma
Metastatic Cancer

Interventions: Drug: CPI-613

First Posted Date: 2008-08-26

Last Posted Date: 2016-12-29

Lead Sponsor: Cornerstone Pharmaceuticals

Target Recruit Count: 39

Registration Number: NCT00741403

Locations: 🇺🇸
Pivotal Research Centers, Peoria, Arizona, United States
🇺🇸
Eastchester Center for Cancer Care, Bronx, New York, United States
🇨🇦
British Columbia Cancer Agency, Vancouver, British Columbia, Canada

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy